Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various bioph…
Biotechnology
US, New York [HQ]
Ratios
7 Sheets · Starting from 2023Margins, Growth Rates In %
| Ratio | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||
| Gross Margin | 100.00 | 92.43 | 43.82 | 95.85 | 99.00 | 99.75 | 76.19 | |
| Profit Margin | 75.72 | 76.76 | 129.45 | 23.34 | 20.91 | 1.91 | 48.20 | |
| Operating Margin | 58.81 | 76.02 | 144.59 | 75.16 | 62.49 | 43.69 | 63.37 | |
|
EPS Growth
|
- - | 13.74 | 65.04 | -79.44 | -12.88 | -91.50 | 2,497.14 | |
| EPS USD | 342.00 | 389.00 | 642.00 | 132.00 | 115.00 | 9.78 | 254.00 | |
| Return on Assets (ROA) | - - | 12.12 | 18.86 | 2.35 | 2.73 | 0.25 | 6.93 | |
| Return on Equity (ROE) | - - | 30.70 | 38.47 | 5.00 | 8.29 | 0.76 | 17.39 | |
| Return on Invested Capital (ROIC) | - - | 8.86 | 18.24 | 3.31 | 4.29 | 1.43 | 7.87 | |
| Solvency | ||||||||
| Equity Ratio | - - | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | - - | 57.34 | 50.11 | 27.57 | 40.51 | 42.33 | 37.45 | |
| Debt/Equity | - - | 145.25 | 102.17 | 58.78 | 122.84 | 126.44 | 94.01 | |
| Debt/EBITDA | - - | 325.06 | 225.78 | 255.45 | 374.81 | 549.81 | 379.20 | |
|
Debt/Capitalization
|
- - | 59.23 | 50.54 | 37.02 | 55.13 | 55.84 | 48.46 | |
| Long-Term Debt/Capitalization | - - | 58.16 | 49.38 | 37.02 | 55.13 | 52.09 | 48.46 | |
| Interest Debt per Share USD | - - | 19.20 | 17.78 | 15.91 | 17.51 | 16.68 | 14.13 | |
| Debt Growth | - - | - - | -4.31 | -6.76 | 22.00 | 0.29 | -13.79 | |
| Liquidity | ||||||||
| Current Ratio | - - | 449.62 | 249.56 | 875.94 | 1,680.71 | 218.97 | 789.58 | |
| Quick Ratio | - - | 445.50 | 249.53 | 659.71 | 1,676.84 | 211.21 | 787.22 | |
| Cash Ratio | - - | 331.66 | 85.08 | 327.72 | 899.88 | 146.62 | 295.59 | |
| Operating Cash Flow Ratio | - - | 200 | 500 | 600 | 1,100 | 100 | 1,800 | |
| Turnover | ||||||||
| Inventory Turnover | - - | 708.27 | - - | 13.41 | - - | - - | - - | |
| Receivables Turnover | - - | 903.65 | 4,680.01 | 5,417.97 | 3,351.63 | 6,113.11 | 303.78 | |
| Payables Turnover | - - | 3,036.86 | 9,119.81 | 817.74 | 409.18 | 71.72 | 3,697.04 | |
|
Asset Turnover
|
- - | 15.79 | 14.57 | 10.06 | 13.07 | 13.31 | 14.37 | |
| Fixed Turnover | - - | - - | - - | - - | - - | - - | - - | |
| Coverage | ||||||||
| Interest Coverage | 379.92 | 487.38 | 976.71 | 1,015.92 | 861.14 | 520.05 | 797.14 | |
| Asset Coverage | - - | 100 | 100 | 300 | 200 | 200 | 200 | |
| Cash Flow Coverage (CFGR) | - - | 24.82 | 26.73 | 34.98 | 28.43 | 30.13 | 49.41 | |
| EBITDA Coverage | 400 | 500 | 900 | 1,100 | 800 | 500 | 700 | |
| Dividend Coverage | -100 | -100 | -300 | -100 | -100 | - - | -300 | |
| Time Interest Earned (TIE) | 200 | 300 | - - | 300 | 200 | 100 | 200 | |
| Market Prospects | ||||||||
| Dividend Yield | 4.66 | 5.17 | 4.54 | 2.12 | 1.73 | 1.93 | 2.85 | |
| Earnings Yield | 7.68 | 8.74 | 14.42 | 2.64 | 2.90 | 0.25 | 9.03 | |
|
Price/Earnings (P/E)
|
1,302.52 | 1,143.97 | 693.31 | 3,794.64 | 3,452.62 | 40,409.74 | 1,107.93 | |
| Price/Earnings Growth (PEG) | - - | 83.24 | 10.66 | -47.77 | -268.09 | -441.66 | 0.44 | |
|
Price/Book (P/B)
|
- - | 351.16 | 266.68 | 189.88 | 286.15 | 307.53 | 192.65 | |
| Price/Tangible Book (P/TB) | - - | 351.16 | 266.68 | 189.88 | 286.15 | 307.53 | 192.65 | |
| Price/Sales (P/S) | 986.33 | 878.09 | 897.48 | 885.53 | 721.98 | 773.65 | 533.99 | |
|
Price/Cash Flow (P/CF)
|
1,111.24 | 973.90 | 976.62 | 923.56 | 819.29 | 807.30 | 414.72 | |
| Price/Free CF (P/FCF) | -1,806.62 | 834.83 | -30,123.80 | 444.06 | 819.08 | 413.57 | 1,372.37 | |
| Price/Operating CF (P/OCF) | 1,111.24 | 973.90 | 976.62 | 923.56 | 819.29 | 807.30 | 414.72 |